TargetMol

Proinsulin C-peptide human acetate

Product Code:
 
TAR-TP1651L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TP1651L-1mg1mg£163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-2mg2mg£217.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-5mg5mg£286.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-10mg10mg£410.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-25mg25mg£622.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-50mg50mg£858.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-100mg100mg£1,139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TP1651L-500mg500mg£2,231.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Proinsulin C-peptide (human) is a polypeptide of 31 amino acid residues that links the A and B chains of proinsulin to ensure proper folding, has biological activity and regulates cellular functions.
CAS:
0
Formula:
C131H215N35O50
Molecular Weight:
3080.31
Purity:
0.9734
SMILES:
O=C(N)CC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H](CO)NC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H]1N(C([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CO)NC(CNC([C@H](C)NC(CNC([C@H]2N(C(CNC(CNC(CNC([C@H](CC(C)C)NC([C@H](CCC(O)=O)NC([C@H](C(C)C)NC([C@H](CCC(N)=O)NC(CNC([C@H](C(C)C)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CCC(O)=O)NC([C@H](C)NC([C@H](CCC(O)=O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC2)=O)=O)=O)=O)=O)=O)=O)CCC1)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O

References

R. S. Mughal, et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia. 2010 Aug;53(8):1761-71.